` ABSI (Absci Corp) vs S&P 500 Comparison - Alpha Spread

ABSI
vs
S&P 500

Over the past 12 months, ABSI has underperformed S&P 500, delivering a return of -35% compared to the S&P 500's +17% growth.

Stocks Performance
ABSI vs S&P 500

Loading
ABSI
S&P 500
Add Stock

Performance Gap
ABSI vs S&P 500

Loading
ABSI
S&P 500
Difference
www.alphaspread.com

Performance By Year
ABSI vs S&P 500

Loading
ABSI
S&P 500
Add Stock

Competitors Performance
Absci Corp vs Peers

S&P 500
ABSI
0KHE
TMO
DHR
207940
Add Stock

Absci Corp
Glance View

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.

ABSI Intrinsic Value
1.49 USD
Overvaluation 48%
Intrinsic Value
Price
Back to Top